MedTrace Logo

Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

NCT00002847 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system to try to stop cancer cells from growing. Combining interferon alfa and interleukin-2 may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer.

Conditions

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

recombinant interferon alfa

PROCEDURE

conventional surgery

Sponsors & Collaborators

  • Blumenthal Cancer Center at Carolinas Medical Center

    lead OTHER

Principal Investigators

  • Richard L. White, MD · Blumenthal Cancer Center at Carolinas Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002847 on ClinicalTrials.gov